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Summary We have investigated the expression of insulin-like growth factor I receptors (IGFR) by the ZR-75-
1 human breast cancer cell line and tamoxifen-resistant (ZR-75-9al) and oestrogen-independent (ZR-PR-LT)
variants. ZR-75-1 cells expressed 6633+953 receptors per cell (Kd 0.24+0.06 nM). IGFR expression was
reduced in ZR-75-9al cells (1180+614 receptors per cell, Kd 0.13+0.05) and increased in the ZR-PR-LT cell
line (18 430+3210 receptors per cell, Kd 0.24+ 17). A comparison of these data with previously published
findings for epidermal growth factor receptor (EGFR) expression by these cell lines revealed that IGFR and
EGFR expression are inversely related in the variant lines whereas ZR-75-1 cells express similar numbers of
both receptors. Since the changes in IGFR expression observed are associated with changes in steroid hormone
receptor status, we also investigated the effects of oestradiol, the synthetic progestin ORG 2058 and
dexamethasone on IGFR expression. Oestradiol increased IGFR expression only in the ZR-75-1 cell line. Low
concentrations ofORG 2058 increased IGFR levels in the two cell lines positive for progesterone receptor (ZR-
75-1 and ZR-PR-LT). High concentrations of ORG 2058 increased IGFR expression in all cell lines, as did
dexamethasone. These data suggest that EGFR and IGFR expression may be linked in breast cancer, and that
EGFR/IGFR ratios in breast cancer may be a more sensitive prognostic indicator than EGFR expression
alone. Regardless of basal IGFR expression by the cell lines studied, ORG 2058 increased IGFR expression,
possibly via both the progesterone and glucocorticoid receptors.
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Epidermal growth factor (EGF) and insulin-like growth
factor I (IGF-I) are potent mitogens in human breast cancer
and both act via membrane-associated receptors with
intrinsic tyrosine kinase activity. The influence of IGF-I in
regulating breast cancer cell proliferation appears to be under
steroid hormone control at a number of levels. Oestrogen has
been reported to up-regulate IGF-I receptor (IGFR)
expression, possibly sensitising tumour cells to the mitogenic
effect of IGF-I (Stewart et al., 1990) and a positive
relationship between oestrogen receptor (ER) and IGFR
expression has been reported (Pekonen et al., 1988).
Conversely, progestins appear to down-regulate IGFR
numbers (Papa et al., 1991; Owens et al., 1993). Tamoxifen
has been reported to reduce circulating levels of IGF-I
(Pollack et al., 1992), and the pattern of expression of IGF
binding proteins (IGFBPs), which can both attenuate and
potentiate the actions of IGF-I, is influenced by both
oestrogens and antioestrogens (Lonning, 1992; Owens et al.,
1993; Lahti et al., 1994; Manni et al., 1994). It is generally
accepted that tumour expression of receptors for epidermal
growth factor (EGFR) is a powerful prognostic indicator in
human breast cancer, with high EGFR numbers being
associated with low ER content and poor clinical prognosis
(Harris, 1989). Recent evidence has suggested that the EGF
and IGF receptor systems may influence one another at
several levels. Administration of EGF or oestradiol to
ovariectomised mice increases uterine IGF-I mRNA produc-
tion (Hana and Murphy, 1994) suggesting that activation of
the IGF receptor system may be a common down-stream
event for both oestradiol- and EGF-induced cell prolifera-
tion. It has been reported that EGF can regulate IGFBP
expression (Andreatta van Leyen et al., 1994; Hembree et al.,
1994). The relationship between EGFR and IGFR expression
is less clear. Since a positive ER status is associated with a
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positivity for IGFR (Pekonen et al., 1988) and low EGFR
levels (Harris, 1989), an inverse relationship between EGFR
and IGFR expression might be anticipated. However such a
relationship has not been clearly demonstrated to date
(Pekonen et al., 1988).
We have previously shown that acquired tamoxifen
resistance accompanied by loss of detectable ERs and
progesterone receptors (PGRs) in the ZR-75-1 human breast
cancer cell line (Van den Berg et al., 1989) is associated with
an increase in EGFR expression (Long et al., 1992), in
agreement with clinical findings (Harris, 1989). Conversely,
an oestrogen-independent variant of the same cell line, which
constitutively expresses high numbers of PGRs (Van den
Berg et al., 1990), has a much reduced EGFR content (Long
et al., 1992). In this study we have characterised IGFR
expression by these cell lines and report that IGFR
expression is inversely related to EGFR expression. In light
of an accompanying positive association between IGFR and
PGR expression, we have also investigated the effects of
progestins on IGFR expression in these cell lines.
Methods
Cell lines
The ZR-75-1 human breast cancer cell line was obtained
from Flow Laboratories, Irvine, UK. Cells were routinely
maintained in RPMI-1640 medium supplemented with 5%
fetal calf serum, 100 IU ml-' penicillin and 100 tg ml-1
streptomycin. ZR-75-9al cells are a tamoxifen-resistant
variant of ZR-75-1 (Van den Berg et al., 1989) routinely
maintained in RPMI-1640 medium in the presence of 8 4UM
tamoxifen. All experiments described were carried out on
cells that had been grown in tamoxifen-free medium for at
least 3 days.
ZR-PR-LT cells are oestrogen independent (Van den Berg
et al., 1990) and routinely maintained in medium lacking
known oestrogenic activity, (RPMI-1640 medium lackingExpression of EGFR and IGFR by ZR-75-1 is inversely related
HW van den Berg et al
478
phenol red and supplemented with heat-treated and dextran-
coated charcoal-stripped fetal calf serum). Steroid and EGF
receptor status of the cell lines is routinely determined and
the phenotypes originally reported (Van den Berg et al., 1989,
1990; Long et al., 1992) have proved to be stable.
Radioiodination of IGF-I
Receptor grade IGF-I (10,g, Penisula Laboratories, St.
Helens, UK) was iodinated using the iodogen method
(Fraker and Speck, 1978) as previously described for EGF
(Long et al., 1992). The radioiodination mixture was
fractionated by reverse-phase high-performance liquid chro-
matography (HPLC) using a Waters Associates gradient
system (Milford, MA, USA) fitted with an analytical Vydac
C4 column. The eluting gradient was trifluoroacetic acid
(TFA)/water (0.05%/99.95% v/v) to TFA/water/acetonitrile
(0.05%/29.95%/70.0% v/v) and the flow rate was
1 ml min-'. Fractions (0.5 ml) were collected and 25 pl
aliquots were taken for determination of radioactivity. Three
major iodinated peak fractions were identified and the
fractions covering these peaks were pooled, aliquoted and
stored at -20°C. These peaks were assumed to represent
monoiodination of IGF-I at each of the tyrosine residues
present in the peptide. Of the three iodinated peaks separated
by HPLC, two demonstrated similar specific binding to ZR-
75-1 cells and variants. The third peak showed no specific
binding and may contain IGF-I iodinated at Tyr', which has
previously been shown to have low affinity for the IGF-I
receptor (Schaffer et al., 1993).
['25I1]IGF-I binding to ZR-75-1 cells and variants
IGFR expression by cells was determined using a whole cell
binding assay as previously described (Long et al., 1992).
Cells (2 x 105) were plated into 24-place multiwell dishes and
allowed to attach for 24 h. ['25I]IGF-I binding was
determined by replacing the medium with RPMI-1640
medium (0.5 ml) supplemented with 1% bovine serum
albumin containing ['25I]IGF-I (0.01 -0.33 nM) in the
absence or presence of a 100-fold excess of non-labelled
IGF-I to determine non-specific binding. Following a 1 h
incubation at 4°C medium was removed and wells rinsed
twice with ice-cold phosphate-buffered saline. Aliquots of
500,l of IM sodium hydroxide were added to each well and
plates incubated for 1 h at 37°C to extract radioactivity.
Radioactivity was determined by scintillation counting,
(LKB Wallac 1410 LSC). Maximum binding capacity (Bmax)
and affinity (Kd) were calculated after linearisation of specific
binding data (Keightly and Cressie, 1980).
Steroid hormone modulation of['25I]IGF-I binding
Cells (5 x 104) were plated into 24-place multiwell dishes and
allowed to attach for 24 h. Medium was then replaced with
medium containing a range of concentrations of oestradiol,
the synthetic progestin ORG 2058 (Amersham International)
or dexamethasone (Sigma-Aldrich, Poole, Dorset, UK). Cells
were incubated for 6 days and [125I]IGF-I binding assessed as
described above using a single concentration of ['25I]IGF-I
(0.2 nM). Data is presented as ['251]IGF-I binding as a
percentage of control after correcting for changes in cell
numbers in the treated groups. Oestradiol treatment (10-8_
10-7 M) increased ZR-75-1 cell numbers by <10%, decreased
ZR-PR-LT cell numbers by 10-40% (Van den Berg et al.,
1990) and had no significant effect on ZR-75-9al cells (Van
den Berg et al., 1989). Dexamethasone and ORG 2058
reduced cell numbers in all cell lines by 5-40% (Van den
Berg et al., 1993).
Statistical analysis
All experiments were carried out in triplicate and data
analysed by a one-way analysis of variance using the Student
Newman-Keuls test.
Results
Figure 1 shows the concentration-dependent binding of
['251]IGF-I to ZR-75-1 cells. Non-specific binding was
typically less than 10% and linearisation of binding data
suggested a single class of specific binding site. Maximum
binding capacity and ligand affinity for the receptor for the
three cell lines studied is shown in Table I. The oestrogen
independent ZR-PR-LT line expressed approximately three
times the number of IGFR compared with the parent ZR-75-
1 line. Conversely, IGFR numbers were greatly reduced in
the tamoxifen-resistant ZR-75-9al line, there being a more
than 15-fold difference between IGFR numbers in this cell
line compared with ZR-PR-LT cells. These changes in IGFR
expression were not accompanied by any significant change in
ligand affinity for the receptor (Table I).
Figure 2 compares IGFR expression in the three cell lines
with previously published data for EGFR expression (Long
et al., 1992). It can be seen that there is a clear inverse
relationship between IGFR and EGFR expression in the
variant cell lines ZR-PR-LT and ZR-75-9al while ZR-75-1
cells express similar numbers of both receptors.
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Figure 1 Total (0-0), non-specific (A-A) and specific binding
(A-A) of [1251]IGF-I to ZR-75-1 cells.
Table I IGF-I receptor expression by ZR-75-1 cells and variants
Bmax
receptors per cell Kd (nM)
ZR-75-1 6633 i953 0.24+ 0.06
ZR-75-9al 1180±614 0.13+0.05
ZR-PR-LT 18 430± 3210 0.24±0.17
Results are means and s.e.m. ofthree determinations
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Figure 2 EGFR (OI) and IGFR (0) expression by ZR-75-1 cells
and variants.
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vExposure of ZR-75-1 cells to oestradiol resulted in a dose-
dependent increase in ['25I]IGF-I binding, (Figure 3).
Oestradiol failed to increase [1251]IGF-I binding in the
tamoxifen-resistant ZR-75-9al cells, which lack oestrogen
receptors (Van den Berg et al., 1989). Oestradiol (10-9 and
10-8 M) caused an approximate 25% decrease in ['251]IGF-I
binding in ZR-PR-LT cells whereas higher concentrations
were without effect. Figure 4 shows the effect of the progestin
ORG 2058 on ['25I]IGF-I binding by ZR-75-1 cells and
variants. Physiological concentrations of ORG 2058 (10-9
and 10-8 M) caused a 40-50% increase in [1251]IGF-I binding
in ZR-75-1 and ZR-PR-LT cells, but had no significant effect
on [1251I]IGF-I binding by ZR-75-9al cells. A 30-50%
increase in binding was observed in all cell lines at 10-7 M
ORG 2058. At higher concentrations [1251]IGF-I binding was
markedly stimulated in the ZR-PR-LT line, whereas the effect
was less marked in the ZR-75-9al line or the parent line.
Since pharmacological concentrations of ORG 2058 may
exert effects via the glucocorticoid receptor we also
investigated the effects of dexamethasone on [1251I]IGF-I
binding. Dexamethasone caused a dose-dependent increase
in [1251]IGF-I binding in all three cell lines, the increase being
greatest in the ZR-PR-LT cell line (Figure 5).
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Figure 3 The effect of oestradiol on specific binding of[125I]IGF-
I to ZR-75-I (f-f), ZR-PR-LT (A-A) and ZR-75-9al (0-0)
cells. Data are presented as means+ s.e.m. of three observations.
*P<0.05, **P<0.001 vs control.
25U
o5 200
{
cJ 0
__' 150
Expression of EGFR and IGFR by ZR-75-1 Is inversely related
HW van den Berg et al !
479
Discussion
We have previously shown that acquisition of tamoxifen
resistance as exemplified by the ZR-75-9al human breast
cancer cell line is associated with an increase in the expression
of EGFR compared with the parent ZR-75-1 line (Long et
al., 1992) and loss of ER and PGR (Van den Berg et al.,
1989). This finding was in accord with clinical observations
that ER-negative/EGFR-positive human breast cancers have
a poor prognosis and are resistant to tamoxifen treatment
(Nicholson, 1988; Harris, 1989). In contrast, the oestrogen-
independent ZR-PR-LT line has much reduced EGFR
numbers accompanying elevated PGR expression (Van den
Berg, 1990). In this study we have shown that these changes
in EGFR expression associated with tamoxifen resistance and
oestrogen independence respectively are paralleled by
opposite changes in IGFR expression (Table I). While the
parent cell line expresses similar numbers of EGFR and
IGFR, in the variant lines, EGFR and IGFR expression is
inversely related (Figure 2). These data suggest that EGFR
and IGFR expression in ZR-75-1 cells are linked, with
changes in the level of expression of one receptor being
reflected by an opposite change in the expression ofthe other.
There is evidence to support the concept of receptor cross-
talk for EGFR and IGFR. Administration of EGF to
ovariectomised mice increases uterine IGF-I mRNA produc-
tion (Hana and Murphy, 1994) and it has been reported that
EGF can regulate IGFBP-3 expression, thus sensitising cells
to the effects of IGF-I. (Andreatta van Leyen et al., 1994;
Hembree et al., 1994). It is possible that EGF sensitising of
cells to IGF may occur more effectively in the face of high
EGFR/low IGFR levels, while sensitisation would be less
effective when EGFR numbers are low, and perhaps
unnecessary when corresponding IGFR numbers are high.
Since there is good evidence that ER and EGFR
expression is inversely related in breast cancer, (Nicholson,
1988; Harris, 1989) and there is a positive relationship
between ER and IGFR expression (Pekonen et al., 1988;
Railo et al., 1994), it might be expected that an inverse
relationship between IGFR and EGFR expression would
exist. Clinical studies have failed to establish such a
relationship (Pekonen et al., 1988; Foekens et al., 1989).
The reasons for this are unknown, but may be due to
inappropriate cut-off points for receptor positivity, occupa-
tion of receptors by endogeneous ligands and other factors.
To our knowledge, our data are the first to show an inverse
relationship between IGFR and EGFR expression in human
breast cancer cell lines in vitro. Whereas EGFR expression is
elevated only 3-fold in the ZR-75-9al tamoxifen-resistant line
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Fiiure 4 The effect of ORG2058 on specific binding of
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Figure 5 The effect of dexamethasone on specific binding of [12 I]IGF-I to ZR-75-I(f-M), ZR-PR-LT (A-A) and ZR-75-9al
(0-0) cells. Data are presented as means+s.e.m. of three
observations. *P<0.05, **P<0.001 vs control.
u
.. --
7-
---
7
7Expression of EGFR and IGFR by ZR-75-1 is inversely related
HW van den Berg et al
480
compared with the parent line (Figure 2), the EGFR/IGFR
ratios in the two cell lines are 0.75 and 12.5 respectively.
Should such a relationship exist in vivo it is possible that an
EGFR/IGFR ratio may provide a more sensitive prognostic
indicator for antioestrogen resistance than EGFR expression
alone.
We have shown that oestradiol increases IGF binding by
the oestrogen-sensitive ZR-75-1 cell line, (Figure 3), in
agreement with earlier studies (Stewart et al., 1990). As
expected, oestradiol was without effect in the ZR-75-9al line,
which lacks oestrogen receptors (Van den Berg et al., 1989).
Although the mechanism is unknown, the observation that
low concentrations of oestradiol reduces ['25I]IGF-I binding
by ZR-PR-LT cells would be consistent with our earlier
findings that oestradiol inhibits ZR-PR-LT cell proliferation
(Van den Berg et al., 1990). Elevated expression of IGFR by
the oestrogen-independent ZR-PR-LT line is consistent with
the observation that another oestradiol-induced protein
(PGR) is also overexpressed in this cell line in the absence
of oestrogenic stimulation (Van den Berg et al., 1990).
[1251]IGF-I binding is also increased in all cell lines by the
synthetic progestin ORG 2058, (Figure 4). A flat dose-
response curve was noted for the parent line, with all
concentrations causing a 40-50% increase in binding.
Physiological concentrations of ORG 2058 (10' and
10-8 M) increased [251I]IGF-I binding only in the cell lines
positive for the presence of PGR, (ZR-75-1 and ZR-PR-LT).
Higher concentrations of ORG 2058 increased ['251]IGF-I
binding in all three cell lines, with the effects being most
marked in the variant lines, where 10-5 M ORG 2058
approximately doubled ['25I]IGF-I binding. In these cell
lines dexamethasone treatment causes a similar increase in
binding (Figure 5), suggesting that a pharmacological
concentration of ORG 2058 may be acting via the
glucocorticoid receptor. Taken together, these data suggest
that [1251]IGF-I binding is increased in the parent line by
ORG 2058 acting primarily via PGR. In the ZR-PR-LT line,
both PGR and the glucocorticoid receptor seem to be
involved, whereas in the ZR-75-9al line the increase in
[I251]IGF-I binding seems to be primarily glucocorticoid
receptor mediated. Confirmation of the relative contribu-
tions of PGR and the glucocorticoid receptor in mediating
the effects of ORG 2058 described will require the use of
specific progestin and glucocorticoid antagonists.
The observation that low concentrations of the progestin
ORG 2058 increase [1251]IGF-I binding in the ZR-75-1 cell
line is in contrast to a previous study that showed that
['251]IGF-I binding by a breast cancer cell line is reduced by
progestins (Papa et al., 1991). However, a different cell line
(T47D) and different progestins (progesterone and R5020)
were used in the latter study and the down regulation of
IGFR reported was attributed to a progestin-induced
increase in IGF-II secretion. The failure of the present
study to demonstrate IGFR down regulation may in part be
explained by the report that ZR-75-1 cells do not secrete
IGF-II (Osborne et al., 1989). Taken together with these
earlier studies, our findings emphasise the complexity of
potential interactions between steroid and peptide growth
factor receptors. To our knowledge, this report is the first to
indicate that IGFR expression may also be increased by
glucocorticoids, and that high concentrations of a progestin
may increase ['251]IGF-I binding via the glucocorticoid
receptor. The physiological significance of these findings is
unclear, as progestins and glucocorticoids are generally
growth inhibitory towards breast cancer cells in vitro and
down regulation of a receptor for a potent mitogen such as
IGF-I would be more consistent with these anti-proliferative
effects. In this context it is of interest that progestins and
glucocorticoids have also been shown to increase EGFR
expression in a number of human breast cancer cell lines
(Ewing et al., 1989).
In conclusion, we have demonstrated an inverse relation-
ship between EGFR and IGFR receptor expression by
human breast cancer cells in vitro. Regardless of basal
IGFR expression by the cell lines studied, [1251]IGF-I binding
is increased following exposure to a progestin and this effect
may be mediated via both PGRs and glucocorticoid
receptors.
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